Top

Published in:

01-02-2015 | Review

The importance of comparative oncology in translational medicine

Authors: Federica Riccardo, Luigi Aurisicchio, Joseph A. Impellizeri, Federica Cavallo

Published in: Cancer Immunology, Immunotherapy | Issue 2/2015

Abstract

Human cancer is so complex that in vivo preclinical models are needed if effective therapies are to be developed. Naturally occurring cancers in companion animals are therefore a great resource, as shown by the remarkable growth that comparative oncology has seen over the last 30 years. Cancer has become a leading cause of death in companion animals now that more pets are living long enough to develop the disease. Furthermore, more owners are seeking advanced and novel therapies for their pets as they are very much considered family members. Living in the same environments, pets and humans are often afflicted by the same types of cancer which show similar behavior and, in some species, express the same antigen molecules. The treatment of pet tumors using novel therapies is of compelling translational significance.

Vargo-Gogola T, Rosen JM (2007) Modelling breast cancer: one size does not fit all. Nat Rev Cancer 7:659–672. doi:10.1038/nrc2193 PubMed

Kao J, Salari K, Bocanegra M, Choi YL, Girard L, Gandhi J et al (2009) Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. PLoS One 4:e6146. doi:10.1371/journal.pone.0006146 PubMedCentralPubMed

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646–674. doi:10.1016/j.cell.2011.02.013 PubMed

Nelson CM, Bissell MJ (2006) Of extracellular matrix, scaffolds, and signaling: tissue architecture regulates development, homeostasis, and cancer. Annu Rev Cell Dev Biol 22:287–309. doi:10.1146/annurev.cellbio.22.010305.104315 PubMedCentralPubMed

Dranoff G (2011) Experimental mouse tumour models: what can be learnt about human cancer immunology? Nat Rev Immunol 12:61–66. doi:10.1038/nri3129 PubMed

Pinho SS, Carvalho S, Cabral J, Reis CA, Gartner F (2012) Canine tumors: a spontaneous animal model of human carcinogenesis. Transl Res 159:165–172. doi:10.1016/j.trsl.2011.11.005 PubMed

Lollini PL, Cavallo F, Nanni P, Forni G (2006) Vaccines for tumour prevention. Nat Rev Cancer 6:204–216. doi:10.1038/nrc1815 PubMed

Bibby MC (2004) Orthotopic models of cancer for preclinical drug evaluation: advantages and disadvantages. Eur J Cancer 40:852–857. doi:10.1016/j.ejca.2003.11.021 PubMed

Julien S, Merino-Trigo A, Lacroix L, Pocard M, Goere D, Mariani P et al (2012) Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer. Clin Cancer Res 18:5314–5328. doi:10.1158/1078-0432.CCR-12-0372 PubMed

10.

Couzin-Frankel J (2014) The littlest patient. Science 346:24–27. doi:10.1126/science.346.6205.24 PubMed

11.

Singh M, Ferrara N (2012) Modeling and predicting clinical efficacy for drugs targeting the tumor milieu. Nat Biotechnol 30:648–657. doi:10.1038/nbt.2286 PubMed

12.

Berns A, Barbacid M (2013) Mouse models of cancer. Mol Oncol 7:143–145. doi:10.1016/j.molonc.2013.02.014 PubMed

13.

Jacob J, Radkevich O, Forni G, Zielinski J, Shim D, Jones RF, Wei WZ (2006) Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice. Cell Immunol 240:96–106. doi:10.1016/j.cellimm.2006.07.002 PubMed

14.

Lollini PL, Cavallo F, De Giovanni C, Nanni P (2013) Preclinical vaccines against mammary carcinoma. Expert Rev Vaccines 12:1449–1463. doi:10.1586/14760584.2013.845530 PubMed

15.

Jonkers J, Berns A (2002) Conditional mouse models of sporadic cancer. Nat Rev Cancer 2:251–265. doi:10.1038/nrc777 PubMed

16.

Bashir T, Cloninger C, Artinian N, Anderson L, Bernath A, Holmes B et al (2012) Conditional astroglial Rictor overexpression induces malignant glioma in mice. PLoS One 7:e47741. doi:10.1371/journal.pone.0047741 PubMedCentralPubMed

17.

Zhu C, Luong R, Zhuo M, Johnson DT, McKenney JK, Cunha GR, Sun Z (2011) Conditional expression of the androgen receptor induces oncogenic transformation of the mouse prostate. J Biol Chem 286:33478–33488. doi:10.1074/jbc.M111.269894 PubMedCentralPubMed

18.

Rongvaux A, Willinger T, Martinek J, Strowig T, Gearty SV, Teichmann LL et al (2014) Development and function of human innate immune cells in a humanized mouse model. Nat Biotechnol 32:364–372. doi:10.1038/nbt.2858 PubMedCentralPubMed

19.

Mestas J, Hughes CC (2004) Of mice and not men: differences between mouse and human immunology. J Immunol 172:2731–2738PubMed

20.

Herodin F, Thullier P, Garin D, Drouet M (2005) Nonhuman primates are relevant models for research in hematology, immunology and virology. Eur Cytokine Netw 16:104–116PubMed

21.

Kantor J, Irvine K, Abrams S, Snoy P, Olsen R, Greiner J et al (1992) Immunogenicity and safety of a recombinant vaccinia virus vaccine expressing the carcinoembryonic antigen gene in a nonhuman primate. Cancer Res 52:6917–6925PubMed

22.

Conry RM, White SA, Fultz PN, Khazaeli MB, Strong TV, Allen KO et al (1998) Polynucleotide immunization of nonhuman primates against carcinoembryonic antigen. Clin Cancer Res 4:2903–2912PubMed

23.

Aurisicchio L, Mennuni C, Giannetti P, Calvaruso F, Nuzzo M, Cipriani B et al (2007) Immunogenicity and safety of a DNA prime/adenovirus boost vaccine against rhesus CEA in nonhuman primates. Int J Cancer 120:2290–2300. doi:10.1002/ijc.22555 PubMed

24.

Fattori E, Aurisicchio L, Zampaglione I, Arcuri M, Cappelletti M, Cipriani B et al (2009) ErbB2 genetic cancer vaccine in nonhuman primates: relevance of single nucleotide polymorphisms. Hum Gene Ther 20:253–265. doi:10.1089/hum.2008.153 PubMed

25.

Vail DM, MacEwen EG (2000) Spontaneously occurring tumors of companion animals as models for human cancer. Cancer Invest 18:781–792PubMed

26.

Paoloni M, Khanna C (2008) Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 8:147–156. doi:10.1038/nrc2273 PubMed

27.

Dickinson PJ, LeCouteur RA, Higgins RJ, Bringas JR, Larson RF, Yamashita Y et al (2010) Canine spontaneous glioma: a translational model system for convection-enhanced delivery. Neuro Oncol 12:928–940. doi:10.1093/neuonc/noq046 PubMedCentralPubMed

28.

Pena L, De Andres PJ, Clemente M, Cuesta P, Perez-Alenza MD (2013) Prognostic value of histological grading in noninflammatory canine mammary carcinomas in a prospective study with two-year follow-up: relationship with clinical and histological characteristics. Vet Pathol 50:94–105. doi:10.1177/0300985812447830 PubMed

29.

Bukowski JA, Wartenberg D, Goldschmidt M (1998) Environmental causes for sinonasal cancers in pet dogs, and their usefulness as sentinels of indoor cancer risk. J Toxicol Environ Health A 54:579–591PubMed

30.

Patronek GJ, Waters DJ, Glickman LT (1997) Comparative longevity of pet dogs and humans: implications for gerontology research. J Gerontol A Biol Sci Med Sci 52:B171–B178PubMed

31.

Mukaratirwa S, Chipunza J, Chitanga S, Chimonyo M, Bhebhe E (2005) Canine cutaneous neoplasms: prevalence and influence of age, sex and site on the presence and potential malignancy of cutaneous neoplasms in dogs from Zimbabwe. J S Afr Vet Assoc 76:59–62PubMed

32.

Waters DJ, Wildasin K (2006) Cancer clues from pet dogs. Sci Am 295:94–101PubMed

33.

Tamburini BA, Trapp S, Phang TL, Schappa JT, Hunter LE, Modiano JF (2009) Gene expression profiles of sporadic canine hemangiosarcoma are uniquely associated with breed. PLoS One 4:e5549. doi:10.1371/journal.pone.0005549 PubMedCentralPubMed

34.

Mack GS (2006) Clinical trials going to the dogs: canine program to study tumor treatment, biology. J Natl Cancer Inst 98:161–162. doi:10.1093/jnci/djj061 PubMed

35.

Lindblad-Toh K, Wade CM, Mikkelsen TS, Karlsson EK, Jaffe DB, Kamal M et al (2005) Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 438:803–819. doi:10.1038/nature04338 PubMed

36.

Mueller F, Fuchs B, Kaser-Hotz B (2007) Comparative biology of human and canine osteosarcoma. Anticancer Res 27:155–164PubMed

37.

Angstadt AY, Thayanithy V, Subramanian S, Modiano JF, Breen M (2012) A genome-wide approach to comparative oncology: high-resolution oligonucleotide aCGH of canine and human osteosarcoma pinpoints shared microaberrations. Cancer Genet 205:572–587. doi:10.1016/j.cancergen.2012.09.005 PubMed

38.

Mooney M, Bond J, Monks N, Eugster E, Cherba D, Berlinski P et al (2013) Comparative RNA-Seq and microarray analysis of gene expression changes in B-cell lymphomas of Canis familiaris. PLoS One 8:e61088. doi:10.1371/journal.pone.0061088 PubMedCentralPubMed

39.

Withrow SJ, Wilkins RM (2010) Cross talk from pets to people: translational osteosarcoma treatments. ILAR J 51:208–213PubMed

40.

Mutsaers AJ (2009) Metronomic chemotherapy. Top Companion Anim Med 24:137–143. doi:10.1053/j.tcam.2009.03.004 PubMed

41.

Gordon IK, Khanna C (2010) Modeling opportunities in comparative oncology for drug development. ILAR J 51:214–220PubMed

42.

Rivera P, von Euler H (2011) Molecular biological aspects on canine and human mammary tumors. Vet Pathol 48:132–146. doi:10.1177/0300985810387939 PubMed

43.

Ranieri G, Gadaleta CD, Patruno R, Zizzo N, Daidone MG, Hansson MG et al (2013) A model of study for human cancer: spontaneous occurring tumors in dogs. Biological features and translation for new anticancer therapies. Crit Rev Oncol Hematol 88:187–197. doi:10.1016/j.critrevonc.2013.03.005 PubMed

44.

Khanna C, London C, Vail D, Mazcko C, Hirschfeld S (2009) Guiding the optimal translation of new cancer treatments from canine to human cancer patients. Clin Cancer Res 15:5671–5677. doi:10.1158/1078-0432.CCR-09-0719 PubMedCentralPubMed

45.

Khanna C, Lindblad-Toh K, Vail D, London C, Bergman P, Barber L et al (2006) The dog as a cancer model. Nat Biotechnol 24:1065–1066. doi:10.1038/nbt0906-1065b PubMed

46.

Paoloni M, Webb C, Mazcko C, Cherba D, Hendricks W, Lana S et al (2014) Prospective molecular profiling of canine cancers provides a clinically relevant comparative model for evaluating personalized medicine (PMed) trials. PLoS One 9:e90028. doi:10.1371/journal.pone.0090028 PubMedCentralPubMed

47.

Paoloni MC, Khanna C (2007) Comparative oncology today. Vet Clin North Am Small Anim Pract 37:1023–1032. doi:10.1016/j.cvsm.2007.08.003 PubMedCentralPubMed

48.

Rowell JL, McCarthy DO, Alvarez CE (2011) Dog models of naturally occurring cancer. Trends Mol Med 17:380–388. doi:10.1016/j.molmed.2011.02.004 PubMedCentralPubMed

49.

Khanna C, Gordon I (2009) Catching cancer by the tail: new perspectives on the use of kinase inhibitors. Clin Cancer Res 15:3645–3647. doi:10.1158/1078-0432.CCR-09-0132 PubMed

50.

Anderson P (2006) Liposomal muramyl tripeptide phosphatidyl ethanolamine: ifosfamide-containing chemotherapy in osteosarcoma. Future Oncol 2:333–343. doi:10.2217/14796694.2.3.333 PubMed

51.

Lequarre AS, Andersson L, Andre C, Fredholm M, Hitte C, Leeb T et al (2011) LUPA: a European initiative taking advantage of the canine genome architecture for unravelling complex disorders in both human and dogs. Vet J 189:155–159. doi:10.1016/j.tvjl.2011.06.013 PubMed

52.

Vaysse A, Ratnakumar A, Derrien T, Axelsson E, Pielberg GR, Sigurdsson S et al (2011) Identification of genomic regions associated with phenotypic variation between dog breeds using selection mapping. PLoS Genet 7:e1002316. doi:10.1371/journal.pgen.1002316 PubMedCentralPubMed

53.

Berglund J, Nevalainen EM, Molin AM, Perloski M, Andre C, Zody MC et al (2012) Novel origins of copy number variation in the dog genome. Genome Biol 13:R73. doi:10.1186/gb-2012-13-8-r73 PubMedCentralPubMed

54.

Sjostrand K, Wess G, Ljungvall I, Haggstrom J, Merveille AC, Wiberg M et al (2014) Breed differences in natriuretic peptides in healthy dogs. J Vet Intern Med 28:451–457. doi:10.1111/jvim.12310 PubMed

55.

London CA, Malpas PB, Wood-Follis SL, Boucher JF, Rusk AW, Rosenberg MP et al (2009) Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Cancer Res 15:3856–3865. doi:10.1158/1078-0432.CCR-08-1860 PubMed

56.

Biller BJ, Elmslie RE, Burnett RC, Avery AC, Dow SW (2007) Use of FoxP3 expression to identify regulatory T cells in healthy dogs and dogs with cancer. Vet Immunol Immunopathol 116:69–78. doi:10.1016/j.vetimm.2006.12.002 PubMed

57.

Biller BJ, Guth A, Burton JH, Dow SW (2010) Decreased ratio of CD8+ T cells to regulatory T cells associated with decreased survival in dogs with osteosarcoma. J Vet Intern Med 24:1118–1123. doi:10.1111/j.1939-1676.2010.0557.x PubMedCentralPubMed

58.

Sherger M, Kisseberth W, London C, Olivo-Marston S, Papenfuss TL (2012) Identification of myeloid derived suppressor cells in the peripheral blood of tumor bearing dogs. BMC Vet Res 8:209. doi:10.1186/1746-6148-8-209 PubMedCentralPubMed

59.

Michael HT, Ito D, McCullar V, Zhang B, Miller JS, Modiano JF (2013) Isolation and characterization of canine natural killer cells. Vet Immunol Immunopathol 155:211–217. doi:10.1016/j.vetimm.2013.06.013 PubMedCentralPubMed

60.

Guth AM, Hafeman SD, Elmslie RE, Dow SW (2013) Liposomal clodronate treatment for tumour macrophage depletion in dogs with soft-tissue sarcoma. Vet Comp Oncol 11:296–305. doi:10.1111/j.1476-5829.2012.00319.x PubMed

61.

Ponce F, Marchal T, Magnol JP, Turinelli V, Ledieu D, Bonnefont C et al (2010) A morphological study of 608 cases of canine malignant lymphoma in France with a focus on comparative similarities between canine and human lymphoma morphology. Vet Pathol 47:414–433. doi:10.1177/0300985810363902 PubMed

62.

Gavazza A, Presciuttini S, Barale R, Lubas G, Gugliucci B (2001) Association between canine malignant lymphoma, living in industrial areas, and use of chemicals by dog owners. J Vet Intern Med 15:190–195PubMed

63.

Hayes HM, Tarone RE, Cantor KP, Jessen CR, McCurnin DM, Richardson RC (1991) Case-control study of canine malignant lymphoma: positive association with dog owner’s use of 2,4-dichlorophenoxyacetic acid herbicides. J Natl Cancer Inst 83:1226–1231PubMed

64.

Miligi L, Costantini AS, Veraldi A, Benvenuti A, Will, Vineis P (2006) Cancer and pesticides: an overview and some results of the Italian multicenter case-control study on hematolymphopoietic malignancies. Ann N Y Acad Sci 1076:366–377. doi:10.1196/annals.1371.036 PubMed

65.

Pastor M, Chalvet-Monfray K, Marchal T, Keck G, Magnol JP, Fournel-Fleury C, Ponce F (2009) Genetic and environmental risk indicators in canine non-Hodgkin’s lymphomas: breed associations and geographic distribution of 608 cases diagnosed throughout France over 1 year. J Vet Intern Med 23:301–310. doi:10.1111/j.1939-1676.2008.0255.x PubMed

66.

Simon D, Moreno SN, Hirschberger J, Moritz A, Kohn B, Neumann S et al (2008) Efficacy of a continuous, multiagent chemotherapeutic protocol versus a short-term single-agent protocol in dogs with lymphoma. J Am Vet Med Assoc 232:879–885. doi:10.2460/javma.232.6.879 PubMed

67.

Gavazza A, Sacchini F, Lubas G, Gugliucci B, Valori E (2009) Clinical, laboratory, diagnostic and prognostic aspects of canine lymphoma: a restrospective study. Comp Clin Pathol 18:291–299

68.

Marconato L, Gelain ME, Comazzi S (2013) The dog as a possible animal model for human non-Hodgkin lymphoma: a review. Hematol Oncol 31:1–9. doi:10.1002/hon.2017 PubMed

69.

Chun R (2009) Lymphoma: which chemotherapy protocol and why? Top Companion Anim Med 24:157–162. doi:10.1053/j.tcam.2009.03.003 PubMed

70.

Higginbotham ML, McCaw DL, Roush JK, Nietfeld JC, Wilkerson MJ, Reeds K, Burr D (2013) Intermittent single-agent doxorubicin for the treatment of canine B-cell lymphoma. J Am Anim Hosp Assoc 49:357–362. doi:10.5326/JAAHA-MS-5929 PubMed

71.

O’Connor CM, Sheppard S, Hartline CA, Huls H, Johnson M, Palla SL et al (2012) Adoptive T-cell therapy improves treatment of canine non-Hodgkin lymphoma post chemotherapy. Sci Rep 2:249. doi:10.1038/srep00249 PubMedCentralPubMed

72.

Sorenmo KU, Krick E, Coughlin CM, Overley B, Gregor TP, Vonderheide RH, Mason NJ (2011) CD40-activated B cell cancer vaccine improves second clinical remission and survival in privately owned dogs with non-Hodgkin’s lymphoma. PLoS One 6:e24167. doi:10.1371/journal.pone.0024167 PubMedCentralPubMed

73.

Marconato L, Frayssinet P, Rouquet N, Comazzi S, Leone VF, Laganga P et al (2014) Randomized, placebo-controlled, double-blinded chemoimmunotherapy clinical trial in a pet dog model of diffuse large B-cell lymphoma. Clin Cancer Res 20:668–677. doi:10.1158/1078-0432.CCR-13-2283 PubMed

74.

Peruzzi D, Gavazza A, Mesiti G, Lubas G, Scarselli E, Conforti A et al (2010) A vaccine targeting telomerase enhances survival of dogs affected by B-cell lymphoma. Mol Ther 18:1559–1567. doi:10.1038/mt.2010.104 PubMedCentralPubMed

75.

Gavazza A, Lubas G, Fridman A, Peruzzi D, Impellizeri JA, Luberto L et al (2013) Safety and efficacy of a genetic vaccine targeting telomerase plus chemotherapy for the therapy of canine B-cell lymphoma. Hum Gene Ther 24:728–738. doi:10.1089/hum.2013.112 PubMedCentralPubMed

76.

Impellizeri JA, Howell K, McKeever KP, Crow SE (2006) The role of rituximab in the treatment of canine lymphoma: an ex vivo evaluation. Vet J 171:556–558. doi:10.1016/j.tvjl.2005.03.005 PubMed

77.

Smith SH, Goldschmidt MH, McManus PM (2002) A comparative review of melanocytic neoplasms. Vet Pathol 39:651–678PubMed

78.

Boston SE, Lu X, Culp WT, Montinaro V, Romanelli G, Dudley RM et al (2014) Efficacy of systemic adjuvant therapies administered to dogs after excision of oral malignant melanomas: 151 cases (2001–2012). J Am Vet Med Assoc 245:401–407. doi:10.2460/javma.245.4.401 PubMed

79.

Bergman PJ (2007) Canine oral melanoma. Clin Tech Small Anim Pract 22:55–60. doi:10.1053/j.ctsap.2007.03.004 PubMed

80.

Spangler WL, Kass PH (2006) The histologic and epidemiologic bases for prognostic considerations in canine melanocytic neoplasia. Vet Pathol 43:136–149. doi:10.1354/vp.43-2-136 PubMed

81.

Simpson RM, Bastian BC, Michael HT, Webster JD, Prasad ML, Conway CM et al (2014) Sporadic naturally occurring melanoma in dogs as a preclinical model for human melanoma. Pigment Cell Melanoma Res 27:37–47. doi:10.1111/pcmr.12185 PubMedCentralPubMed

82.

Gillard M, Cadieu E, De Brito C, Abadie J, Vergier B, Devauchelle P et al (2014) Naturally occurring melanomas in dogs as models for non-UV pathways of human melanomas. Pigment Cell Melanoma Res 27:90–102. doi:10.1111/pcmr.12170 PubMed

83.

Fowles JS, Denton CL, Gustafson DL (2013) Comparative analysis of MAPK and PI3K/AKT pathway activation and inhibition in human and canine melanoma. Vet Comp Oncol. doi:10.1111/vco.12044 PubMed

84.

Freeman KP, Hahn KA, Harris FD, King GK (2003) Treatment of dogs with oral melanoma by hypofractionated radiation therapy and platinum-based chemotherapy (1987–1997). J Vet Intern Med 17:96–101PubMed

85.

Proulx DR, Ruslander DM, Dodge RK, Hauck ML, Williams LE, Horn B et al (2003) A retrospective analysis of 140 dogs with oral melanoma treated with external beam radiation. Vet Radiol Ultrasound 44:352–359PubMed

86.

Murphy S, Hayes AM, Blackwood L, Maglennon G, Pattinson H, Sparkes AH (2005) Oral malignant melanoma—the effect of coarse fractionation radiotherapy alone or with adjuvant carboplatin therapy. Vet Comp Oncol 3:222–229. doi:10.1111/j.1476-5810.2005.00082.x PubMed

87.

Westberg S, Sadeghi A, Svensson E, Segall T, Dimopoulou M, Korsgren O et al (2013) Treatment efficacy and immune stimulation by AdCD40L gene therapy of spontaneous canine malignant melanoma. J Immunother 36:350–358. doi:10.1097/CJI.0b013e31829d8a1b PubMed

88.

Finocchiaro LM, Glikin GC (2012) Cytokine-enhanced vaccine and suicide gene therapy as surgery adjuvant treatments for spontaneous canine melanoma: 9 years of follow-up. Cancer Gene Ther 19:852–861. doi:10.1038/cgt.2012.72 PubMed

89.

Kyte JA, Mu L, Aamdal S, Kvalheim G, Dueland S, Hauser M et al (2006) Phase I/II trial of melanoma therapy with dendritic cells transfected with autologous tumor-mRNA. Cancer Gene Ther 13:905–918. doi:10.1038/sj.cgt.7700961 PubMed

90.

Alexander AN, Huelsmeyer MK, Mitzey A, Dubielzig RR, Kurzman ID, Macewen EG, Vail DM (2006) Development of an allogeneic whole-cell tumor vaccine expressing xenogeneic gp100 and its implementation in a phase II clinical trial in canine patients with malignant melanoma. Cancer Immunol Immunother 55:433–442. doi:10.1007/s00262-005-0025-6 PubMed

91.

Bergman PJ, McKnight J, Novosad A, Charney S, Farrelly J, Craft D et al (2003) Long-term survival of dogs with advanced malignant melanoma after DNA vaccination with xenogeneic human tyrosinase: a phase I trial. Clin Cancer Res 9:1284–1290PubMed

92.

Grosenbaugh DA, Leard AT, Bergman PJ, Klein MK, Meleo K, Susaneck S et al (2011) Safety and efficacy of a xenogeneic DNA vaccine encoding for human tyrosinase as adjunctive treatment for oral malignant melanoma in dogs following surgical excision of the primary tumor. Am J Vet Res 72:1631–1638. doi:10.2460/ajvr.72.12.1631 PubMed

93.

Bergman PJ, Camps-Palau MA, McKnight JA, Leibman NF, Craft DM, Leung C et al (2006) Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center. Vaccine 24:4582–4585. doi:10.1016/j.vaccine.2005.08.027 PubMed

94.

Ottnod JM, Smedley RC, Walshaw R, Hauptman JG, Kiupel M, Obradovich JE (2013) A retrospective analysis of the efficacy of Oncept vaccine for the adjunct treatment of canine oral malignant melanoma. Vet Comp Oncol 11:219–229. doi:10.1111/vco.12057 PubMed

95.

Mayayo SL, Prestigio S, Maniscalco L, La Rosa G, Arico A, De Maria R et al (2011) Chondroitin sulfate proteoglycan-4: a biomarker and a potential immunotherapeutic target for canine malignant melanoma. Vet J 190:e26–e30. doi:10.1016/j.tvjl.2011.02.020 PubMed

96.

Campoli M, Ferrone S, Wang X (2010) Functional and clinical relevance of chondroitin sulfate proteoglycan 4. Adv Cancer Res 109:73–121. doi:10.1016/B978-0-12-380890-5.00003-X PubMed

97.

Riccardo F, Iussich S, Maniscalco L, Lorda Mayayo S, La Rosa G, Arigoni M et al (2014) CSPG4-specific immunity and survival prolongation in dogs with oral malignant melanoma immunized with human CSPG4 DNA. Clin Cancer Res 20:3753–3762. doi:10.1158/1078-0432.CCR-13-3042 PubMed

98.

Ordas J, Millan Y, Dios R, Reymundo C, de Las Mulas JM (2007) Proto-oncogene HER-2 in normal, dysplastic and tumorous feline mammary glands: an immunohistochemical and chromogenic in situ hybridization study. BMC Cancer 7:179. doi:10.1186/1471-2407-7-179 PubMedCentralPubMed

99.

Millanta F, Calandrella M, Citi S, Della Santa D, Poli A (2005) Overexpression of HER-2 in feline invasive mammary carcinomas: an immunohistochemical survey and evaluation of its prognostic potential. Vet Pathol 42:30–34. doi:10.1354/vp.42-1-30 PubMed

100.

Uva P, Aurisicchio L, Watters J, Loboda A, Kulkarni A, Castle J et al (2009) Comparative expression pathway analysis of human and canine mammary tumors. BMC Genom 10:135. doi:10.1186/1471-2164-10-135

101.

Wiese DA, Thaiwong T, Yuzbasiyan-Gurkan V, Kiupel M (2013) Feline mammary basal-like adenocarcinomas: a potential model for human triple-negative breast cancer (TNBC) with basal-like subtype. BMC Cancer 13:403. doi:10.1186/1471-2407-13-403 PubMedCentralPubMed

102.

Shafiee R, Javanbakht J, Atyabi N, Bahrami A, Kheradmand D, Safaei R et al (2013) Comparative value of clinical, cytological, and histopathological features in feline mammary gland tumors; an experimental model for the study of human breast cancer. Diagn Pathol. 8:136. doi:10.1186/1746-1596-8-136 PubMedCentralPubMed

103.

Soares M, Correia J, Rodrigues P, Simoes M, de Matos A, Ferreira F (2013) Feline HER2 protein expression levels and gene status in feline mammary carcinoma: optimization of immunohistochemistry (IHC) and in situ hybridization (ISH) techniques. Microsc Microanal 19:876–882. doi:10.1017/S1431927613001529 PubMed

104.

Peruzzi D, Mesiti G, Ciliberto G, La Monica N, Aurisicchio L (2010) Telomerase and HER-2/neu as targets of genetic cancer vaccines in dogs. Vaccine 28:1201–1208. doi:10.1016/j.vaccine.2009.11.031 PubMed

105.

Rankin KS, Starkey M, Lunec J, Gerrand CH, Murphy S, Biswas S (2012) Of dogs and men: comparative biology as a tool for the discovery of novel biomarkers and drug development targets in osteosarcoma. Pediatr Blood Cancer 58:327–333. doi:10.1002/pbc.23341 PubMed

106.

Boerman I, Selvarajah GT, Nielen M, Kirpensteijn J (2012) Prognostic factors in canine appendicular osteosarcoma—a meta-analysis. BMC Vet Res 8:56. doi:10.1186/1746-6148-8-56 PubMedCentralPubMed

107.

Schmidt AF, Nielen M, Klungel OH, Hoes AW, de Boer A, Groenwold RH, Kirpensteijn J (2013) Prognostic factors of early metastasis and mortality in dogs with appendicular osteosarcoma after receiving surgery: an individual patient data meta-analysis. Prev Vet Med. 112:414–422. doi:10.1016/j.prevetmed.2013.08.011 PubMed

108.

Finocchiaro LM, Villaverde MS, Gil-Cardeza ML, Riveros MD, Glikin GC (2011) Cytokine-enhanced vaccine and interferon-beta plus suicide gene as combined therapy for spontaneous canine sarcomas. Res Vet Sci 91:230–234. doi:10.1016/j.rvsc.2010.12.012 PubMed

Title: The importance of comparative oncology in translational medicine
Authors: Federica Riccardo
Luigi Aurisicchio
Joseph A. Impellizeri
Federica Cavallo
Publication date: 01-02-2015
Publisher: Springer Berlin Heidelberg
Published in: Cancer Immunology, Immunotherapy / Issue 2/2015
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-014-1645-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2015

Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease

N-3 polyunsaturated fatty acids inhibit IFN-γ-induced IL-18 binding protein production by prostate cancer cells

Maitake mushroom extract in myelodysplastic syndromes (MDS): a phase II study

Tumor ablation by intratumoral Ra-224-loaded wires induces anti-tumor immunity against experimental metastatic tumors

CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo

Benefit of adjuvant interferon alfa-2b (IFN-α) therapy in melanoma patients with high serum MMP-8 levels

Keynote webinar | Spotlight on antibody–drug conjugates in cancer